Dyne Therapeutics, Inc.
- Open
- 24.99
- Day high
- 25.31
- Day low
- 24.86
- Prev close
- 25.43
- Volume
- 56K
- Mkt cap
- $4.6B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.6
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$113.5M over the last 3 months (2 open-market buys, 46 sales)
- 🏛Institutions accumulating (13F)
Dyne Therapeutics, Inc. (DYN) is a Healthcare company listed on NASDAQ. The stock is up 84% over the past year. Over the trailing 3 months, insiders filed 2 open-market buys and 46 sales (SEC Form 4).
Dyne Therapeutics, Inc. (DYN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DYN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 30, 2026 | $-0.75 | $-1.08 | -44.2% | — | — |
| May 11, 2026 | $-0.77 | $-0.73 | +5.5% | — | — |
| Nov 5, 2025 | $-0.81 | $-0.76 | +6.2% | — | — |
| May 8, 2025 | $-0.88 | $-1.05 | -19.3% | — | — |
| Feb 27, 2025 | $-0.92 | $-0.88 | +4.3% | — | — |
| May 2, 2024 | $-0.81 | $-0.81 | +0.0% | — | — |
| Mar 5, 2024 | $-0.92 | $-1.09 | -18.5% | $4M | — |
| Aug 3, 2023 | $-0.81 | $-1.08 | -33.3% | — | — |
| May 11, 2023 | $-0.77 | $-0.78 | -1.3% | — | — |
| Mar 2, 2023 | $-0.84 | $-0.74 | +11.9% | — | — |
| Nov 3, 2022 | $-0.95 | $-0.80 | +15.8% | — | — |
| Aug 4, 2022 | $-0.79 | $-1.01 | -27.8% | — | — |
DYN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Lucera Erickofficer: Chief Financial Officer | Sell | 1,797 | $26.28 |
| Aug 17, 2026 | Rhodes Jason Pdirector | Sell | 94,415 | $26.20 |
| Aug 17, 2026 | Rhodes Jason Pdirector | Sell | 1,359,674 | $25.00 |
| Aug 17, 2026 | Rhodes Jason Pdirector | Sell | 322,465 | $25.00 |
| Aug 17, 2026 | Rhodes Jason Pdirector | Sell | 478,377 | $25.00 |
| Aug 17, 2026 | Friedl-Naderer Johannaofficer: Chief Commercial Officer | Sell | 226 | $26.28 |
| Aug 17, 2026 | Rhodes Jason Pdirector | Sell | 63,643 | $26.20 |
| Aug 17, 2026 | Kerr Douglasofficer: Chief Medical Officer | Sell | 1,556 | $26.28 |
| Aug 17, 2026 | Cox Johndirector, officer: CEO & President | Sell | 4,986 | $26.28 |
| Aug 17, 2026 | Rhodes Jason Pdirector | Sell | 268,354 | $26.20 |
| Jul 29, 2026 | Kersten Dirkdirector | Sell | 5,388 | $26.04 |
| Jul 29, 2026 | Kersten Dirkdirector | Sell | 256,072 | $25.50 |
| Jul 8, 2026 | Rhodes Jason Pdirector | Sell | 253,039 | $22.79 |
| Jul 8, 2026 | Rhodes Jason Pdirector | Sell | 29,587 | $23.62 |
| Jul 8, 2026 | Rhodes Jason Pdirector | Sell | 127,182 | $22.79 |
Source: DYN SEC Form 4 filings, latest Aug 17, 2026. For informational purposes only — not investment advice.
See the full DYN insider & 13F page →Dyne Therapeutics, Inc. company profile
Overview
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. The company went public in September 2020 and focuses exclusively on developing innovative therapeutics for genetically driven muscle diseases. Dyne operates as a specialized muscle disease company, leveraging its proprietary FORCE platform technology to advance potential treatments for rare and devastating muscular conditions that currently have limited or no therapeutic options.
Business
Dyne Therapeutics operates in the biotechnology sector, specifically focusing on rare muscle diseases caused by genetic mutations. The company's core technology is the FORCE platform, which stands for "Functional Oligonucleotide Restoration through Cellular Enhancement." This platform is designed to deliver disease-modifying therapeutics directly to muscle tissues, including skeletal muscle, cardiac muscle, and metabolic muscle systems. The FORCE platform works by using specially engineered molecules called antisense oligonucleotides (ASOs) that are conjugated with antibodies. These antibody-oligonucleotide conjugates can target specific muscle tissues and modify the expression of disease-causing genes. In simple terms, the platform acts like a molecular delivery system that can carry therapeutic instructions directly to diseased muscle cells, potentially correcting or compensating for genetic defects that cause muscle dysfunction. Dyne's primary therapeutic programs target three major muscle diseases: Myotonic Dystrophy Type 1 (DM1), a progressive muscle-wasting disease that affects multiple organ systems; Duchenne Muscular Dystrophy (DMD), a severe form of muscular dystrophy that primarily affects boys and leads to progressive muscle degeneration; and Facioscapulohumeral Dystrophy (FSHD), a genetic muscle disorder that causes progressive weakness in facial, shoulder, and upper arm muscles. The company also explores applications for other rare skeletal muscle diseases and cardiac/metabolic muscle conditions. As a clinical-stage company, Dyne currently generates no revenue from product sales, with all financial resources dedicated to research and development activities.
Revenue model
As a pre-revenue biotechnology company, Dyne Therapeutics does not currently generate income from product sales or services. The company operates on a research and development model typical of clinical-stage biotech firms, funding its operations through equity financing, including its initial public offering and subsequent stock offerings. The company's future revenue model will depend on successfully developing its therapeutic candidates through clinical trials and obtaining regulatory approval. Once products reach the market, Dyne would likely generate revenue through direct product sales to hospitals, specialty pharmacies, and healthcare systems that treat patients with rare muscle diseases. Given the rare disease focus, the company would probably employ a high-price, low-volume strategy typical of orphan drugs, potentially charging hundreds of thousands of dollars per patient annually. The company may also pursue licensing agreements or partnerships with larger pharmaceutical companies, which could provide upfront payments, milestone payments, and royalties. Several factors could significantly impact Dyne's future profitability. Positive clinical trial results would increase the likelihood of regulatory approval and commercial success, while negative results could halt development programs entirely. The rare disease market generally supports premium pricing due to limited treatment options and small patient populations, but regulatory agencies and payers increasingly scrutinize high drug prices. Competition from other biotechnology companies developing treatments for the same conditions could pressure pricing and market share. Additionally, the company's cash burn rate of over $100 million annually means it will need continued access to capital markets or partnership deals to fund operations until it achieves profitability, making it vulnerable to broader biotech market sentiment and investor appetite for risk.
Competitive moat
Dyne Therapeutics possesses a moderate but potentially significant competitive moat centered around its proprietary FORCE platform technology. The company's primary competitive advantage lies in its specialized expertise in muscle-targeting drug delivery, which represents a technically challenging area that requires deep scientific knowledge and extensive intellectual property protection. The FORCE platform's ability to deliver therapeutic oligonucleotides specifically to muscle tissues could provide a meaningful differentiation from traditional systemic approaches that may have limited tissue penetration or cause unwanted side effects. However, Dyne's moat faces several vulnerabilities. The biotechnology industry is highly competitive, with numerous companies pursuing similar antisense oligonucleotide approaches and muscle disease targets. Large pharmaceutical companies with substantially greater resources could potentially develop competing technologies or acquire smaller competitors. The company's intellectual property, while important, may not provide insurmountable barriers to entry for well-funded competitors. Additionally, the clinical development process introduces significant execution risk - even superior technology can fail if clinical trials do not demonstrate adequate safety and efficacy. The strength of Dyne's moat will ultimately depend on clinical trial outcomes and the company's ability to demonstrate clear therapeutic advantages over existing treatments or competing approaches. Success in early-stage trials for multiple indications could establish Dyne as a leader in muscle-targeted therapeutics, but failure in key programs could quickly erode any competitive advantages. The rare disease focus provides some protection from competition due to smaller market sizes, but also limits the overall commercial opportunity and makes the company vulnerable to competitive threats in its core therapeutic areas.
Risks & safety
Dyne Therapeutics presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but significant operational risks. • Cash Position: Strong liquidity with $472 million in cash and short-term investments as of Q1 2025, providing substantial runway given current burn rates • Debt Level: Minimal debt with debt-to-equity ratio of only 0.035, indicating very low financial leverage and solvency risk • Cash Burn: High quarterly cash burn of approximately $106 million in Q1 2025, suggesting roughly 4-5 quarters of runway at current spending levels • Current Ratio: Excellent short-term liquidity with current ratio of 20.4, indicating strong ability to meet immediate obligations • Valuation Metrics: Trading at negative earnings multiples due to losses, but Graham net-net working capital value of 5.7 suggests potential asset value protection • Revenue Risk: Zero revenue generation creates complete dependence on successful clinical development and eventual product commercialization • Dilution Risk: Will likely require additional equity financing within 12-18 months, potentially causing significant shareholder dilution
Recent development
Based on the available financial data, Dyne Therapeutics has been in a period of intensive research and development investment, with operating losses increasing from $165 million in 2022 to $315 million in 2024. This escalation in spending suggests the company has been advancing multiple clinical programs simultaneously and potentially expanding its development pipeline. The company significantly strengthened its balance sheet during this period, with cash and short-term investments growing from $172 million at the end of 2022 to over $600 million by mid-2024, indicating successful capital raising activities that have provided substantial funding for continued operations. The increasing cash burn rate, from approximately $157 million in 2022 to $295 million in 2024, reflects the typical progression of a biotechnology company moving its therapeutic candidates through more expensive later-stage clinical trials. This pattern suggests Dyne has been advancing its FORCE platform programs through various phases of clinical development, likely conducting multiple studies across its target indications of myotonic dystrophy, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy. The company's ability to maintain minimal debt levels while funding this expansion demonstrates disciplined financial management and successful equity market access during a period when many biotechnology companies faced challenging fundraising conditions.
DYN company profile · for informational purposes only — not investment advice.
Track DYN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free